EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Effects of Therapies on Proteinuria and eGFR in IgA Nephropathy

Dana Kim iD, Brendon L Neuen iD, Vlado Perkovic, Muh Geot Wong iD

Clinical Journal of the American Society of Nephrology · 2025-12 · 20 (12) · 1753-1766

DOI: 10.2215/cjn.0000000839 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Journal of the American Society of Nephrology, online erschienen am 10.09.2025. Verfasst von Dana Kim und 3 weiteren Autor:innen. Beteiligte Einrichtung: The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Key Points Existing and novel therapies reduce proteinuria and slow eGFR rate of decline in IgA nephropathy, with some heterogeneity across drug classes. Benefits and limitations of each drug class must be considered, and longer-term Phase 3 data on several therapies are awaited. Emerging data support the potential of novel therapies to improve kidney outcomes in IgA nephropathy in the near future.

Background

Substantial advances have been made in therapeutics for IgA nephropathy. We conducted a systematic review and meta-analysis to evaluate the comparative efficacy and safety of existing and novel IgA nephropathy therapies.

Methods

We searched MEDLINE and Embase databases from inception to May 21, 2025, for Phase 2b and 3 multicenter, randomized, placebo-controlled trials enrolling patients with IgA nephropathy that reported treatment effects on proteinuria and/or eGFR slope. Trials were categorized into four drug classes: Nonimmunologic therapies, corticosteroids, B-cell modulating agents, and complement inhibitors. Treatment effects on proteinuria and eGFR slope were pooled overall and by drug class using random-effects meta-analysis.

Results

Fourteen trials were identified of which proteinuria and eGFR outcomes were available in 13 trials (93%) and seven trials (50%), respectively. Pooled data demonstrated all therapies reduced proteinuria, although the magnitude of effect varied across classes: −34% with nonimmunologic therapies, −51% with corticosteroids, −45% with B-cell modulating agents, and −35% with complement inhibitors ( P heterogeneity

Schlagwörter

Stichwörter der Autor:innen

IgA nephropathyclinical trialprimary glomerulonephritis

Autor:innen und Institutionen

  • The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.
  • Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
  • Department of Renal Medicine, Royal North Shore Hospital, Sydney, New South Wales, Australia.
  • Department of Renal Medicine, Concord Repatriation General Hospital, Sydney, New South Wales, Australia.

ORCID-Profile: Dana Kim, Brendon L Neuen, Muh Geot Wong

Zitieren

APA

Kim, D., Neuen, B. L., Perkovic, V., & Wong, M. G. (2025). Effects of Therapies on Proteinuria and eGFR in IgA Nephropathy. Clinical Journal of the American Society of Nephrology, 20(12), 1753-1766. https://doi.org/10.2215/cjn.0000000839

Vancouver

Kim D, Neuen BL, Perkovic V, Wong MG. Effects of Therapies on Proteinuria and eGFR in IgA Nephropathy. Clinical Journal of the American Society of Nephrology. 2025;20(12):1753-1766. doi:10.2215/cjn.0000000839

BibTeX
@article{Kim2025,
  author = {Kim, Dana and Neuen, Brendon L and Perkovic, Vlado and Wong, Muh Geot},
  title = {Effects of Therapies on Proteinuria and eGFR in IgA Nephropathy},
  journal = {Clinical Journal of the American Society of Nephrology},
  year = {2025},
  volume = {20},
  number = {12},
  pages = {1753--1766},
  doi = {10.2215/cjn.0000000839}
}
Kostenlos starten →